Inovio Pharmaceuticals

American biotechnology company

Nasdaq ISIN US45773H4092 SEC CIK 1055726 LEI 529900B9W875XDZXTM97
Follow Inovio Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $298.9K
Net income −$49.2M −8.2% vs same quarter last year
EPS, diluted −$0.50 +42.5% vs same quarter last year
Operating cash flow −$15.3M +29.2% vs same quarter last year
Revenue by quarter
$117K
$65.3K
$0
$0
$0
$0
$0
$298.9K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$400M−$300M−$200M−$100M$0$100MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$65.3K−$85M
FY24$217.8K−$107M
FY23$832K−$135M
FY22$10.3M−$279.8M
FY21$1.8M−$303.7M
FY20$7.4M−$166.4M
FY19$4.1M−$119.4M
FY18$30.5M−$97M
FY17$42.2M−$88.2M
FY16$35.4M−$73.7M
FY15$40.6M−$29.2M
FY14$10.5M−$36.1M
FY13$13.5M−$66M
FY12$4.1M−$19.7M
FY11$9.8M−$15.3M
MarginsShare of revenue
  • Operating margin
  • Net margin
−150000%−100000%−50000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−132871.3%−130082.8%
FY24−51616.9%−49137.6%
FY23−17300.3%−16225.8%
FY22−2607.4%−2726.7%
FY21−16972.3%−17109.9%
FY20−1674.2%−2245.4%
FY19−2702.1%−2902.8%
FY18−308.7%−318.1%
FY17−198.1%−208.9%
FY16−215.5%−208.5%
FY15−84.5%−71.9%
FY14−377.7%−345.4%
FY13−145.1%−490.3%
FY12−570.4%−477.6%
FY11−220.9%−155.7%
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$88.9M
FY24−$104.6M
FY23−$124.7M
FY22−$217.2M
FY21−$216.9M
FY20−$179.5M
FY19−$98.8M
FY18−$75.6M
FY17−$73.5M
FY16−$65.3M
FY15−$15.2M
FY14−$31.2M
FY13−$15.6M
FY12−$22.5M
FY11−$19.9M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Inovio Pharmaceuticals
  • Healthcare median
−150000%−100000%−50000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearInovio PharmaceuticalsHealthcare median
FY25−130082.8%−30.6%
FY24−49137.6%−47%
FY23−16225.8%−58%
FY22−2726.7%−80.4%
FY21−17109.9%−71.9%
FY20−2245.4%−62.2%
FY19−2902.8%−46.3%
FY18−318.1%−49.6%
FY17−208.9%−45.9%
FY16−208.5%−36%
FY15−71.9%−38.4%
FY14−345.4%−35.5%
FY13−490.3%−37.1%
FY12−477.6%−29.1%
FY11−155.7%−27.9%